Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEED: Irinotecan Plus Capecitabine in HER2 Negative Metastatic Breast Cancer
NCT01501669Phase 3Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
irinotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01501669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01501669.